{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:46:10Z","timestamp":1747183570236,"version":"3.40.5"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Noavartis Pharma France"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This observational, prospective study assessed, in a daily clinical practice, the molecular response, safety, quality of life (QoL) and treatment adherence in 183 patients with chronic myeloid leukaemia in chronic phase (CML\u2010CP), receiving nilotinib as first\u2010line treatment. Premature study termination before 24\u00a0months of follow\u2010up occurred in 61 patients (33\u00b73%), and was essentially due to nilotinib treatment discontinuation (<jats:italic>n<\/jats:italic>\u00a0=\u00a053; 29%), motivated by treatment intolerance (<jats:italic>n<\/jats:italic>\u00a0=\u00a029; 15\u00b78%) and inefficacy (<jats:italic>n<\/jats:italic>\u00a0=\u00a019; 10\u00b74%). After 24\u00a0months of treatment, 112\/122 patients (91\u00b78%) had a molecular assessment, 95\u00b75% of whom achieved a major molecular response (MMR), 32\u00b71% achieved uMR<jats:sup>4<\/jats:sup>, defined as an undetectable molecular disease with 4\u2010log molecular response sensitivity (\u226510\u00a0000 <jats:italic>ABL1<\/jats:italic> transcripts). The Morisky Green Levine Medication Adherence Scale was completed by 94\/122 patients (77\u00b70%), and 89\u00b74% of these patients obtained a satisfactory level of treatment adherence, defined as a score \u22653. Patients\u2019 QoL was good at baseline and stable during the follow\u2010up period. The two most common nilotinib\u2010related adverse events (AEs) were pruritus (14\u00b78%) and asthenia (13\u00b77%). Seven patients (3\u00b78%) experienced at least one cardiovascular ischaemic AE. This French nationwide cohort study provides relevant information in daily clinical practice indicating that nilotinib is a valuable first\u2010line treatment option for CML\u2010CP patients.<\/jats:p>","DOI":"10.1111\/bjh.16145","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T23:59:51Z","timestamp":1565308791000},"page":"615-626","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice"],"prefix":"10.1111","volume":"187","author":[{"given":"Fran\u00e7oise","family":"Huguet","sequence":"first","affiliation":[{"name":"Department of Haematology Toulouse University Cancer Institute Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Michel","family":"Cayuela","sequence":"additional","affiliation":[{"name":"Laboratory of Haematology University Hospital Saint\u2010Louis AP\u2010HP and EA3518, University Paris Diderot Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Cambier","sequence":"additional","affiliation":[{"name":"Department of Oncology and Haematology Saint Vincent de Paul Hospital Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Carpentier","sequence":"additional","affiliation":[{"name":"Novartis Pharma S.A.S. Rueil\u2010Malmaison France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malka","family":"Tindel","sequence":"additional","affiliation":[{"name":"Novartis Pharma S.A.S. Rueil\u2010Malmaison France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Violet","sequence":"additional","affiliation":[{"name":"Novartis Pharma S.A.S. Rueil\u2010Malmaison France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Zunic","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospital Centre, Saint\u2010Pierre Reunion Island France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axelle","family":"Lascaux","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology and Cell Therapy Haut\u2010L\u00e9v\u00eaque Hospital, Bordeaux University Hospital Pessac France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-4954","authenticated-orcid":false,"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Institut Bergoni\u00e9 Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"AdheRMC Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213520261"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4155\/cli.14.129"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13108"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144949"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.06.006"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347575"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.348"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31323"},{"key":"e_1_2_8_13_1","unstructured":"EORTC Data Centre. (2001)The EORTC QLQ\u2010C30 3rd edn.http:\/\/www.eortc.be\/qol\/files\/SCManualQLQ-C30.pdf. Accessed 12 June 2018."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095158"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14022"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2372-z"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.181"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.270"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63"},{"key":"e_1_2_8_24_1","unstructured":"International Conference on Harmonisation (ICH) Steering Committee. (2003)ICH Harmonized Tripartite Guideline. Post\u2010Approval Safety Data Management: Definitions and Standards for Expedited Reporting E2D.https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2D\/Step4\/E2D_Guideline.pdf. Accessed 12 June 2018."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-277152"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-358135"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00080-2"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198601000-00007"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082511"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31411"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0958-6"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.01.001"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1219338"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.69.1.67"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16145","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16145","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16145","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T21:52:11Z","timestamp":1693950731000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,8]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1111\/bjh.16145"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16145","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2019,8,8]]},"assertion":[{"value":"2019-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}